

# Index

## A

- Acute coronary syndrome (ACS), 102, 137, 139, 193, 196, 197, 223  
  aspirin, 229  
  CCTA, 226  
  therapies for, 229
- Acute myocardial infarction (AMI)  
  clinical presentation, 198  
  diagnosis of, 199  
  management disparities, 199, 200  
  mortality rates, 191  
  nontraditional and emerging risk factors, 197, 198  
  outcomes, post, 200–204  
  pathophysiologic differences, 192–195  
  research, disparities in, 204, 205  
  traditional risk factors, 195–197
- AF. *See* Atrial fibrillation (AF)
- AFL. *See* Atrial flutter (AFL)
- Alcohol-induced cardiomyopathy, 68
- Aldosterone antagonists, 295
- Aldosterone receptor antagonists, 54
- Ambulatory blood pressure monitoring (ABPM), 39–41
- AMI. *See* Acute myocardial infarction (AMI)
- Aminothiols, 112
- Amyloidosis  
  ATTR, 83, 84  
  familial transthyretin-related amyloidosis, 66
- Angiotensin converting enzyme inhibitor (ACEI), 41, 53, 117, 150, 229
- Angiotensin II (Ang II) type 2 (AT2), 305
- Angiotensin II-Receptor Neprilysin Inhibitor (ARNI), 54
- Angiotensin receptor blockers (ARBs), 53, 54
- Anthracyclines, 308  
  adverse effects of, 304  
  pre-clinical and clinical development, 304, 305
- Anti-arrhythmic drug, 276
- Anti-ischemic therapies, 151, 152, 228, 229
- Antiplatelet agents, 117, 289, 290
- Antithrombotics, 290, 291
- Anxiety disorders, 175, 176
- Arrhythmogenic right ventricular cardiomyopathy (ARVC), 70, 256
- ART. *See* Assisted reproductive technology (ART)
- ARVC. *See* Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Aspirin, 229, 289, 290
- Assisted reproductive technology (ART), 80, 82–84, 86
- Asymmetric dimethylarginine (ADMA), 112
- Atherosclerosis  
  androgen, in CHD, 6, 7  
  at cellular level, 3, 4  
  estrogens, role of, 4–6  
  gender-related differences, 9  
  hs-CRP, 112  
  pathophysiology, 3  
  plaque morphology, 2, 3  
  risk factors in gender, 7, 8  
  sex hormones, role of, 5  
  testosterone and vascular biology, 6
- Atherosclerosis Risk in Communities (ARIC) study, 218
- Atherosclerotic cardiovascular disease (ASCVD) risk, 108, 109, 222
- Atherothrombosis, 290
- Athlete's heart, 84, 85

- Atorvastatin, 118
- Atrial fibrillation (AF), 247  
 cardiovascular outcomes and mortality, 281  
 clinical implications, 252, 253  
 epidemiology, 248, 249  
 gender differences, mechanism of, 272, 273  
 clinical presentation, 273, 274  
 incidence, 273  
 management and outcomes, 250–252  
 normal cardiac electrophysiology, 271, 272  
 presentation and pathophysiology, 250  
 and thromboembolism  
 anticoagulation, 280, 281  
 atrial remodeling, 278, 279  
 increased stasis, 279  
 procoagulant factors, 279  
 vascular factor, 279  
 treatment of  
 anti-arrhythmic drug use, 276  
 catheter ablation, 276, 277  
 electrical cardioversion, 276  
 management of, 274  
 in rate control, 274, 275
- Atrial flutter (AFL)  
 clinical implications, 252  
 epidemiology, 248  
 management and outcomes, 252  
 presentation and pathophysiology, 250
- Atrial tachycardia (AT), 254
- Atrioventricular nodal re-entry tachycardia (AVNRT), 252, 254
- Atrioventricular reentry tachycardia (AVRT), 253
- Autoimmune disorders, 109
- B**
- Bacterial translocation, 94
- Bacteroides* enterotype, 90
- Bacteroidetes, 90, 92
- Becker muscular dystrophies, 67
- $\beta$ -blockers, 52, 53, 117, 151, 291, 292
- Bikini medicine, 217
- Biomarkers, 112, 113
- Bisoprolol, 52, 292
- Bone-marrow stem-cell transplantation, 121
- Breast cancer chemotherapy-induced cardiotoxicity, 51
- Breast cancer therapy  
 cardio-oncology, 309, 310  
 cardiovascular toxicity, early detection of, 309  
 combination of treatments, 308  
 hormonal therapy, 305  
 radiation therapy, 305  
 adverse cardiovascular effects, 307  
 pre-clinical research, 306, 307  
 systemic chemotherapy, 304, 305  
 targeted therapies (*see* Targeted therapies)
- Brugada syndrome (BrS), 258
- C**
- Calcium channel blockers (CCB), 118, 148, 151, 294
- Captopril, 288
- Cardiac arrhythmias  
 conduction system disease, 261  
 EKG, sex differences in, 248  
 familial arrhythmia syndromes  
 BrS, 258  
 CPVT, 258, 259  
 ERS, 259  
 long QT syndromes, 257, 258  
 SQTs, 259  
 ICD therapy, 259, 260  
 SCA, 260, 261  
 sex differences, 262  
 SVT (*see* Supraventricular tachycardia (SVT))
- VA  
 ARVC/D, 256  
 HCM, 257  
 IHD, 255, 256  
 NIDCM, 256  
 sarcoidosis, 257  
 ventricular tachycardia in structurally normal hearts, 254, 255
- Cardiac biomarkers, 199
- Cardiac nuclear magnetic resonance imaging (CMRI), 111, 112, 139, 143
- Cardiac resynchronization therapy (CRT), 56, 113, 114, 247
- Cardiac syndrome X (CSX), 103, 105
- Cardiac transplantation, 56
- Cardiomyopathies  
 ARVC, 70  
 classification, 79  
 definition, 79  
 familial dilated cardiomyopathy, 67, 68  
 familial hypertrophic cardiomyopathy (*see* Familial hypertrophic cardiomyopathy)  
 non-compaction cardiomyopathy, 71  
 non-familial dilated cardiomyopathy, 68  
 alcohol-induced cardiomyopathy, 68  
 myocarditis, 68  
 peripartum cardiomyopathy, 69  
 sarcoidosis, 69  
 non-familial hypertrophic cardiomyopathy  
 athlete's heart, 84, 85

- SSA, 85, 86
- non-familial RCM, 71
- RCM, 70, 71
- Tako-Tsubo cardiomyopathy, 72
- Cardiovascular disease (CVD)
  - ART, 83
  - awareness in women, 342
  - diagnosis of (*see* Microvascular angina (MVA))
  - disparate CVD outcomes, in rural and urban women, 345
  - geographic and gender differences, 336, 337
  - geographic location and outcomes, 337
  - gut microbiome (*see* Gut microbiome)
  - health behaviors, 169
    - ideal cardiovascular health metrics, 172, 173
    - sleep, 173
    - smoking, 170, 171
    - weight, diet and physical inactivity, 171, 172 (*see also* Ischemic heart disease (IHD))
  - in India, 317, 318
    - deaths in females, 323
    - epidemiology, 318–320
    - hypertensive heart disease, 323
    - IHD and stroke, 322
    - NPCDCS, 327, 328
    - RHD, 320, 321
    - risk factors, in women, 323–326
    - STEMI challenge, 328–330
    - strategies for reduction, 326
    - targeting maternal nutrition, 327
  - MetS (*see* Metabolic syndrome (MetS))
  - minorities in U.S., 340, 341
  - neighborhood characteristics, 338–340
  - neighborhood segregation, 341, 342
  - psychosocial influences
    - anxiety, 175, 176
    - depression, 176, 177
    - psychological stress, 174, 175
  - resilience
    - definition, 177
    - dispositional optimism, 177, 178
    - interventions, 179
    - social integration and support, 178
  - rural vs. urban population, 337, 338
  - sex and sociodemographic factors, 166
  - race and ethnicity, 166–168
  - SES, 168, 169
  - stroke awareness, 342, 343
  - treatment
    - delay in women, 343, 344
    - differences by ethnicity, 344
- WCH, 41
- women, risk in, 86
  - ART, 82–84
  - endometriosis, 82
  - fertility therapy failure, 84
  - miscarriage, 84, 85
  - parity, 85
  - PCOS, 81
  - POF, 81, 82
  - pregnancy history, 79
  - stress test, 79, 80
- Cardiovascular drugs, 287
  - aldosterone antagonists, 295
  - antithrombotics, 290, 291
  - aspirin, 289, 290
  - $\beta$ -blockers, 291, 292
  - CCBs, 294
  - digoxin, 291
  - diuretics and RAAS inhibitors, 294, 295
  - gender-specific therapeutic and adverse effects, 296
  - isosorbide mononitrate, 294
  - long QT syndrome, 292, 293
  - pharmacokinetic, 288, 289
  - statins, 289
  - transgender patients, treatment for, 295, 296
- Cardiovascular health and disease (CHD)
  - androgen, role of, 6, 7
  - estrogen, role of, 4–6
- Carnitine deficiency, 84
- Carvedilol, 52, 117
- Catecholaminergic polymorphic ventricular tachycardia (CPVT), 258, 259
- Catheter ablation therapy, 252, 276, 277
- Cognitive behavioral therapy, 121
- Conduction system disease, 261
- Coronary angiography, 145
- Coronary artery bypass grafting (CABG), 219, 239, 242, 344
- Coronary artery calcium (CAC) score, 226
- Coronary artery disease (CAD), 136
  - AMI, 193, 198
  - CAC score, 226
  - CCTA, 143, 144, 226
  - coronary angiography, 145
  - ETT, 225
  - mortality, 219
  - non-obstructive, 220, 222, 230
    - clinical presentation, 108
    - vs. obstructive, 219
  - obstructive, 103, 220, 224, 228
  - prevalence of, 218
  - traditional risk factors, 220
- Coronary artery spasm, 106

- Coronary atherosclerosis, 117
- Coronary computed tomography angiography (CCTA), 137, 143, 144, 226
- Coronary blood flow reserve (CFR), 103, 114, 115, 139, 140, 148, 241
- AMI, 193
  - PET, 111
  - stress echocardiography, 110
  - TTDE, 144
- Coronary heart disease (CHD), 166, 169, 173, 175, 335
- mortality rates, 337
  - prevalence of, 337
  - public awareness, 342
  - risk factors, 338
- Coronary microvascular dysfunction (CMD), 101, 109, 117, 141
- AMI, 193, 194
  - between men versus women, 241
  - classifications of, 103
  - diagnosis of (*see* Microvascular angina (MVA))
  - etiologies, 102
  - long-term management of, 230
  - no obstructive CAD
    - ACE-inhibitors, 117
    - L-Arginine, 118
    - CCBs, 118
    - clinical presentation, 108
    - CMR, 111, 112
    - coronary artery spasm, 106
    - PCs, 113
    - PET, 111
    - pharmacotherapies (*see* Pharmacotherapy)
    - ranolazine, 119
    - risk factors, 108, 109
    - SCAD, 106, 107
    - sestrogen, 119
    - stress cardiomyopathy, 107, 108
    - TCA, 120
  - pathophysiology, 105
- Coronary reactivity testing (CRT), 113, 114
- Coronary revascularization
- CABG, 239, 242
  - CathPCI registry, 242
  - clinical presentation, 241
  - DAPT, 242
  - FAME study, 241
  - patient characteristics between men and women, 240
  - PCI, 239
  - PROSPECT study, 240
  - STEMI, 242
  - stent type, 241
- Coronary vascular dysfunction (CVD), 138, 140
- Cryoballoon technique, 252
- D**
- DCM. *See* Familial dilated cardiomyopathy (DCM)
- Deadly quartet, 16
- Depression, 109, 176, 177
- Dexrazoxane, 305
- Diabetes, 340
- Diabetes self-management education (DSME) programs, 340
- Diastolic blood pressure (DBP), 36, 39
- Digoxin, 55, 291
- Diltiazem, 118
- Dispositional optimism, 177, 178
- Duchenne (DMD), 67
- Duration of dual antiplatelet therapy (DAPT), 242
- Dyslipidemia, 24, 25
- E**
- Early menopause, 81
- Early repolarization syndrome (ERS), 259
- Electrical cardioversion, 276
- Electrocardiography (EKG), 248
- Endometriosis, 82
- Endothelial dysfunction (ED), 104, 105, 140
- Endothelial function, 104
- Endothelium derived hyperpolarizing factor (EDHF), 6
- Endotoxemia, 94
- Enhanced external counterpulsation (EECP), 120, 152
- Enhancing Recovery in Coronary Heart Disease (ENRICH) trial, 176
- Enteric pathogens, 94
- Enterotypes, 90, 91
- Exercise treadmill testing (ETT), 110, 225
- F**
- Fabry's disease, 82, 83
- Familial arrhythmia syndromes
- BrS, 258
  - CPVT, 258, 259
  - ERS, 259
  - long QT syndromes, 257, 258
  - SQTS, 259
- Familial dilated cardiomyopathy (DCM), 67, 68
- Familial hypertrophic cardiomyopathy

- amyloidosis, ATTR, 83, 84
- carnitine deficiency, 84
- Fabry's disease, 82, 83
- HCM, 81, 82
- Familial transthyretin-related amyloidosis (ATTR), 83, 84
- Fascicular ventricular tachycardia (FVT), 255
- Fasudil, 120
- Felodipine, 288
- Fertility therapy failure, 84
- Flow-mediated dilatation (FMD), 144
- Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) study, 241
- Framingham risk score (FRS), 220
  
- G**
- Gestational diabetes (GDM), 197
- Global Burden of Disease (GBD) study, 319
- Gut microbiome
  - adult males and females, 90, 91
  - bacterial translocation, 94
  - endotoxemia, 94
  - enteric pathogens, 94
  - IBS, 94
  - infections, 94, 95
  - obesity, role of, 92, 93
  - TMAO, 93
- Gynecomastia, 295
  
- H**
- HCM. *See* Hypertrophic cardiomyopathy (HCM)
- Heart failure (HF)
  - breast cancer chemotherapy-induced cardiotoxicity, 51
  - clinical manifestations and diagnosis of, 50
  - management of
    - ACE inhibitor, 53
    - aldosterone receptor antagonists, 54
    - ARBs, 53, 54
    - ARNI, 54
    - $\beta$ -blockers, 52, 53
    - cardiac transplantation, 56, 57
    - CRT, 56
    - digoxin, 55
    - hydralazine and isosorbide dinitrate, 54, 55
    - ICD, 55
    - LVADs, 56
  - peripartum cardiomyopathy, 51
  - in women, 49, 50
- Heart failure with preserved ejection fraction (HFpEF), 50, 51
- Heart failure with reduced ejection fraction (HFrEF), 53
- Hidden atherosclerosis, 141
- High-density lipoprotein (HDL), 24, 25, 119
- Highly sensitive-C reactive protein (hs-CRP), 112, 197
- Hispanic Health Paradox, 167
- Hispanic mortality paradox, 177
- Hormonal therapy, 305
- Hormone replacement therapy (HRT), 82, 151, 290
- Hyperglycemia, 16
- Hypertension
  - abnormal ABPM phenotypes, 40, 41
  - definition, 22
  - diagnosis of, 40
  - estrogen, 23
  - gender and racial inequalities, 36
  - and obesity
    - in Black population, 36
    - higher DBP in men, 39
    - in Hispanic population, 37
    - increased visceral adiposity, 37, 38
    - leptin, 39
    - LVH, 39
    - prevalence of, 36
  - pathophysiology, 22
  - in pregnancy, 43
  - prevalence of, 35, 325
  - RAS, 23
  - special population
    - following menopause, 42
    - OCP, 42
    - in pregnancy, 42, 43
  - treatment, 41, 42
- Hypertensive heart disease, 323
- Hypertriglyceridemic waist, 16
- Hypertrophic cardiomyopathy (HCM), 80–82, 257
- Hysterectomy, 82
  
- I**
- ICD therapy. *See* Implantable cardioverter-defibrillator (ICD) therapy
- Imipramine, 152
- Implantable cardioverter-defibrillator (ICD) therapy, 55, 70, 247, 255, 256, 259, 260
- Insulin resistance, 23, 24
- Intravascular ultrasound (IVUS), 143, 146
- Invasive coronary endothelial function testing, 146, 147

- Invasive testing  
 coronary angiography, 145  
 coronary flow and pressure, 145, 146  
 IHD, 227, 228  
 invasive coronary endothelial function testing, 146, 147  
 IVUS, 146
- Irritable Bowel Disease (IBS), 94
- Ischemic heart disease (IHD), 191  
 diagnosis, 224  
 invasive testing, 227, 228  
 noninvasive testing, 224–227  
 epidemiology  
 cardiovascular mortality, 219  
 clinical presentation, 218, 219  
 healthcare cost burden, 220  
 incidence, 218  
 obstructive vs. non-obstructive CAD, 219  
 prevalence, 218  
 quality of life, 220  
 in India, 322  
 microvascular and endothelial dysfunction, 222  
 mortality, 101  
 noninvasive testing  
 anatomic testing, 226, 227  
 functional testing, 224–226  
 microvascular testing, 227  
 no obstructive CAD  
 ETT, 110  
 lifestyle modifications, 115  
 prevention, risk assessment, 222, 223  
 risk factors, 108, 220, 221  
 treatment  
 ACS, therapies for, 229  
 anti-ischemic medical therapy, 228, 229  
 specific conditions in women, therapies for, 229, 230  
 therapeutic lifestyle intervention, 228  
 unique and emerging risk factors, 221, 222  
 VA, 255, 256
- Ischemic non-embolic stroke, 279
- Isosorbide mononitrate, 294
- Ivabradine therapy, 120, 152
- L**
- L-Arginine, 118
- Left atrial enlargement (LAE), 250
- Left ventricular assist devices (LVADs), 56
- Left ventricular ejection fraction (LVEF), 51, 308
- Left ventricular hypertrophy (LVH), 39, 80–82, 84
- Left ventricular outflow tract (LVOT), 254
- Leptin, 39
- Lipid core burden index (LCBI), 240
- Long QT syndrome, 257, 258, 292, 293
- Low-density lipoprotein (LDL), 24, 25, 119
- LQTS. *See* Long QT syndromes (LQTS)
- M**
- Management of Acute Coronary Event (MACE) registry, 326
- Masked hypertension, 41
- Menopausal hormone therapy (MHT), 230
- Metabolic syndrome (MetS)  
 definition, 196  
 diagnosis of, 37, 38  
 characterization, 16  
 components of  
 dyslipidemia, 24, 25  
 hypertension, 22, 23  
 insulin resistance, 23, 24  
 obesity, 25, 26  
 CVD, gender differences in, 26, 27  
 diagnostic criteria, 16–18  
 epidemiology, 19, 21, 22  
 IDF, 16–19  
 phenotype of, 37  
 prevalence of, 15, 37, 38  
 risk factors, 37  
 treatment, gender disparity in, 27
- Metoprolol succinate, 52
- MetS. *See* Metabolic syndrome (MetS)
- Microvascular angina (MVA)  
 ACS, 139  
 CMD, 138  
 coronary blood flow, abnormalities in, 138  
 CVD and CMD  
 CCTA, 143, 144  
 CMRI and SPECT, 143  
 coronary angiography, 145  
 coronary flow and pressure measurements, 145, 146  
 ECG exercise testing, 142  
 invasive coronary endothelial function testing, 146, 147  
 IVUS, 146  
 non-invasive assessment of endothelial function, 144, 145  
 poor quality of life, 142  
 price of misdiagnosis, 141  
 prognosis, 147, 148

- symptom, 141, 142
    - TTDE, 144
  - epidemiology, 136, 137
  - normal, 136
  - obstructive disease, 137
  - pathophysiology
    - coronary vascular dysfunction, 140
    - endothelial dysfunction, 140
    - hidden atherosclerosis, 141
    - myocardial ischemia, 139, 140
    - reduced CFR, 139, 140
  - prognosis, 148
  - syndrome X, 138
  - vascular dysfunction, management of
    - ACE-inhibitors, 150
    - anti-ischemic therapies, 151, 152
    - antiplatelet therapy, 149, 150
    - clinical decision making, 152, 153
    - lifestyle changes, 149
    - statins, 150
  - vasospastic and vasotonic angina, 139
  - Microvascular endothelial dysfunction, 3
  - Microvascular rarefaction, 121
  - Monomorphic ventricular tachycardia (MMVT), 254
  - Myocardial infarction (MI), 50, 166, 218, 219
  - Myocardial ischemia, 139, 140
  - Myocardial perfusion reserve index (MPRI), 112
  - Myocardial structural abnormalities, 103
  - Myocarditis, 68
- N**
- National Health and Nutrition Examination Survey (NHANES), 172
  - National Health Interview Survey (NHIS), 172
  - National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), 327, 328
  - Nebivolol, 117
  - Nicorandil, 120
  - Nifedipine, 118
  - Non vitamin K antagonist oral anticoagulants (NOACs), 281
  - Noncalcified and mixed coronary plaques, 143
  - Non-communicable diseases (NCDs), 317, 323
  - Non-compact cardiomyopathy, 71
  - Non-familial dilated cardiomyopathy
    - alcohol-induced cardiomyopathy, 68
    - myocarditis, 68
  - peripartum cardiomyopathy, 69
  - sarcoidosis, 69
  - Non-familial hypertrophic cardiomyopathy
    - athlete's heart, 84, 85
    - SSA, 85, 86
  - Non-familial restrictive cardiomyopathy, 71
  - Non-Hispanic Blacks (NHBs), 175
  - Non-Hispanic Whites (NHWs), 175
  - Non-invasive testing
    - CCTA, 143
    - CMRI and SPECT, 143, 144
    - ECG exercise testing, 142, 143
    - endothelial function, non-invasive
      - assessment of, 144, 145
    - IHD, 224
      - anatomic testing, 226, 227
      - functional testing, 224–226
      - microvascular testing, 227
    - TTDE, 144
  - Non-ischemic dilated cardiomyopathy (NIDCM), 256
  - Non-ST elevation myocardial infarction (NSTEMI), 192
- O**
- Obesity
    - gut microbiome, 92, 93
    - hypertension, 36–38
      - in Black population, 36
      - higher DBP in men, 39
      - in Hispanic population, 37
    - increased visceral adiposity, 37, 38
    - leptin, 39
    - LVH, 39
    - prevalence of, 36
    - MetS, 25, 26
  - Oral contraceptive medications (OCP), 42
  - Ovarian hyper-stimulation syndrome (OHSS), 83
- P**
- Parity, 85
  - PCOS. *See* Polycystic ovarian syndrome (PCOS)
  - Percutaneous coronary intervention (PCI), 199–201, 203, 204, 219, 239, 241, 242, 344
  - Peripartum cardiomyopathy, 51, 69
  - Peripheral reactive hyperemia index (PRHI), 227
  - Pharmacokinetics, 288, 289

- Pharmacotherapy  
  antiplatelet agents, 117  
  effects of drug, 115, 116  
  statins, 115, 117  
Physical activity (PA), 171  
Pioglitazone, 118  
Plaque morphology, 2, 3  
Plaque rupture, 192, 193  
Polycystic ovarian syndrome (PCOS), 24, 81, 82, 222  
Positron emission tomography (PET), 111  
Post-traumatic stress disorder (PTSD), 196  
Pre-eclampsia, 109  
Premature ovarian failure (POF), 81, 82  
*Prevotella* enterotype 2, 90  
Primary anovulation, 82  
Primary reperfusion method, 344  
Prinzmetal's angina, 106  
Progenitor cells (PC), 113  
Pulseless electrical activity (PEA), 260
- R**  
Radiation therapy, 305, 306  
  adverse cardiovascular effects, 307  
  pre-clinical research, 306, 307  
Ramipril, 118  
Ranolazine, 119, 230  
RCM. *See* Restrictive cardiomyopathy (RCM)  
Reduced coronary flow reserve (CFR), 139, 140  
Renin-angiotensin system (RAS), 23  
Renin-angiotensin-aldosterone system (RAAS), 38, 294, 295  
Restrictive cardiomyopathy (RCM), 70, 71  
Reynold's risk score, 223  
RHD. *See* Rheumatic heart disease (RHD)  
Rheumatic fever (RF), 320  
Rheumatic heart disease (RHD), 320, 321  
Rheumatoid arthritis (RA), 109  
Right ventricular outflow tract (RVOT), 254  
*Ruminococcus* enterotype 3, 90
- S**  
Sarcoidosis, 69, 257  
SCA. *See* Sudden cardiac death (SCA)  
Senile systemic amyloidosis (SSA), 85, 86  
Short QT syndrome (SQTS), 259  
Single nucleotide polymorphisms (SNPs), 104  
Single-photon emission computed tomography (SPECT), 112, 143  
Socioeconomic status (SES), 168, 169  
Spontaneous coronary artery dissection (SCAD), 106, 107  
ST elevated myocardial infarction (STEMI), 192, 199, 201, 239, 240, 242, 328–330  
Stable angina, 108  
Statins, 115, 117, 150, 289  
Stress cardiomyopathy, 107, 108.  
  *See also* Tako-Tsubo cardiomyopathy  
Stress echocardiography, 110  
Stress test, 79, 80  
Stroke  
  anticoagulation, 280  
  NOAC, 281  
  warfarin, 280, 281  
  atrial remodeling, 278, 279  
  awareness, 342, 343  
  increased stasis, 279  
  in India, 322  
  procoagulant factors, 279  
  vascular factors, 279, 280  
Sudden cardiac death (SCA), 260, 261  
Supraventricular tachycardia (SVT)  
  AF  
  clinical implications, 252  
  epidemiology, 248  
  management and outcomes, 250–252  
  presentation and pathophysiology, 250  
  AFL  
  clinical implications, 252  
  epidemiology, 248  
  management and outcomes, 252  
  presentation and pathophysiology, 250  
  AT, 254  
  AVNRT, 252  
  AVRT, 253, 254  
  clinical implications, 254  
  WPW, 253, 254  
  SVT. *See* Supraventricular tachycardia (SVT)  
Sympathetic nervous system (SNS), 38  
Syndrome X, 16, 138  
Systemic chemotherapy, 304, 305  
Systemic lupus erythematosus (SLE), 109  
Systolic blood pressure (SBP), 36
- T**  
Tako-Tsubo cardiomyopathy, 72, 107, 108  
Tamoxifen, 308  
Targeted therapies  
  cardiotoxicity of, 308  
  trastuzumab, 307  
Thin cap fibroatheroma (TCFA), 193



Thromboembolism. *See* Stroke  
Thrombolysis in myocardial infarction (TIMI), 199  
Toll-like receptors (TLRs), 8  
Transthoracic doppler echocardiography (TTDE), 144  
Trastuzumab, 51, 307–309  
Tricyclic antidepressants (TCA), 120  
Trimetazidine, 120  
True hypertrophic cardiomyopathy, 79  
Typical angina, 108

**V**

Vascular endothelium, 103  
Vasospastic angina, 106, 139  
Vasotonic angina, 139  
Ventricular arrhythmias (VA)  
  ARVC/D, 256  
  HCM, 257  
  IHD, 255, 256  
  NIDCM, 256

  sarcoidosis, 257  
  ventricular tachycardia in structurally normal hearts, 254, 255  
Ventricular fibrillation (VF), 258  
Ventricular premature beats (VPBs), 254  
Verapamil, 118, 288  
Very low-density lipoprotein (VLDL) cholesterol, 24  
Vitamin K antagonists (warfarin), 280, 281

**W**

White coat hypertension (WCH), 40, 41  
Wolf-Parkinson-White (WPW) syndrome, 253–254  
Women's Ischemia Syndrome Evaluation (WISE) study, 3, 4, 105, 114, 144, 193, 197, 219, 253

**X**

Xanthines, 230